



Notice Regarding the Commencement of Sales of the Human 3D Skin Model **"REPROSKIN™"**

October 9, 2026


REPROCELL Inc. (the "Company") today announced the commencement of sales of its human three-dimensional (3D) skin model, "REPROSKIN™." REPROSKIN™ is a full-thickness human skin model developed through research and development with Durham University in the United Kingdom, based on Alvetex® technology, the Company's proprietary 3D cell culture technology. It reproduces the structural and biological characteristics of human skin and can be used for a wide range of research applications, including studies on skin diseases, wound healing, pigmentation, and skin aging, as well as drug discovery, preclinical testing, and safety assessment.

REPROSKIN™ is produced by culturing human-derived keratinocytes and fibroblasts within Alvetex®. It has a stratified, full-thickness skin structure and reproduces structures and functions that closely resemble those of living tissue, including extracellular matrix production and a barrier function similar to that of human skin. In addition, because the product is supplied as living tissue mounted in a dedicated culture vessel, it can be used in a variety of research protocols.

Professor Stefan Przyborski, Chief Scientific Officer (CSO) of REPROCELL Europe Ltd., a REPROCELL Group company, and Professor of Cell Technology at Durham University, commented:

"REPROSKIN™ is a robust and highly reproducible research platform that accurately reproduces the anatomical and physiological features of human skin tissue. By offering REPROSKIN™ both as a research product and through contract services, we believe we can provide significant value to researchers engaged in skin biology and skincare research."

The impact of this matter on the Company's financial results for the current fiscal year is expected to be minimal at this time; however, the Company will promptly disclose any matters requiring disclosure should they arise.



Cross-sectional image of REPROSKIN™